EA199900358A1 - Производные 3-алкоксиизоксазол-4-илзамещенных 2-аминокарбоновых кислот - Google Patents

Производные 3-алкоксиизоксазол-4-илзамещенных 2-аминокарбоновых кислот

Info

Publication number
EA199900358A1
EA199900358A1 EA199900358A EA199900358A EA199900358A1 EA 199900358 A1 EA199900358 A1 EA 199900358A1 EA 199900358 A EA199900358 A EA 199900358A EA 199900358 A EA199900358 A EA 199900358A EA 199900358 A1 EA199900358 A1 EA 199900358A1
Authority
EA
Eurasian Patent Office
Prior art keywords
group
disease
hydrogen
substituted
cycloalk
Prior art date
Application number
EA199900358A
Other languages
English (en)
Other versions
EA001625B1 (ru
Inventor
Бенни Банг-Андерсен
Клаус Петер Бегесе
Повль Крогсгор-Ларсен
Ленс Сибюлле Мольтсен
Original Assignee
Х. Лундбекк А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Х. Лундбекк А/С filed Critical Х. Лундбекк А/С
Publication of EA199900358A1 publication Critical patent/EA199900358A1/ru
Publication of EA001625B1 publication Critical patent/EA001625B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/12—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Производные (3-алкоксиизоксазол-4-ил)замещенных 2-аминокарбоновых кислот и их серусодержащие аналоги общей формулы (I) или (II)где Rпредставляет водород, алкил, алкенил, алкинил, циклоалк(ен)ил, циклоалк(ен)ил-алк(ен/ин)ил или необязательно замещенный фенил-алк(ен/ин)ил; А представляет связь или углеводородную спейсерную группу; В представляет группу –CR(NRR)-COOR, где R-Rпредставляют, независимо, водород или алкил, и Rимеет те же значения, что и R, или представляет пивалоилоксиметил, или В представляет группу формулы (III), где R, Rи Rвыбирают независимо среди водорода, неароматической углеводородной группы, фенил- и тиенилалкила и гетероалифатической группы, или Rи Rсоединяются, образуя в результате алкиленовую, алкениленовую или алкиниленовую группу, или Rи Rсоединяются с образованием алкиленовой, алкениленовой или алкиниленовой группы, необязательно замещенной гидрокси или метилом, или с образованием группы СН-О-СН; Е представляет COOR, где Rимеет те же значения, что и R, или Е представляет тетразолил или триазолил; Х представляет О или S; и Y представляет О или S; являются лигандами рецепторов для возбудительных аминокислот (ЕАА), в частности, АМРА- и/или NMDA-рецепторов, полезными при лечении церебральной ишемии, болезни Гентингтона, эпилептических нарушений, болезни Паркинсона, болезни Альцгеймера, шизофрении, боли, депрессии или страха.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA199900358A 1996-10-04 1997-10-03 Производные 3-алкоксиизоксазол-4-илзамещенных 2-аминокарбоновых кислот EA001625B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK109296 1996-10-04
PCT/DK1997/000426 WO1998015542A1 (en) 1996-10-04 1997-10-03 3-alkoxyisoxazol-4-yl-substituted 2-amino carboxylic acid compounds

Publications (2)

Publication Number Publication Date
EA199900358A1 true EA199900358A1 (ru) 1999-10-28
EA001625B1 EA001625B1 (ru) 2001-06-25

Family

ID=8100908

Family Applications (1)

Application Number Title Priority Date Filing Date
EA199900358A EA001625B1 (ru) 1996-10-04 1997-10-03 Производные 3-алкоксиизоксазол-4-илзамещенных 2-аминокарбоновых кислот

Country Status (26)

Country Link
US (1) US6200999B1 (ru)
EP (1) EP0934286B1 (ru)
JP (1) JP2001501630A (ru)
KR (1) KR20000048908A (ru)
CN (1) CN1238766A (ru)
AR (1) AR008880A1 (ru)
AT (1) ATE230734T1 (ru)
AU (1) AU733004B2 (ru)
BG (1) BG103348A (ru)
BR (1) BR9712198A (ru)
CA (1) CA2268028C (ru)
CZ (1) CZ116899A3 (ru)
DE (1) DE69718338T2 (ru)
EA (1) EA001625B1 (ru)
ES (1) ES2189978T3 (ru)
HU (1) HUP0000084A3 (ru)
IL (1) IL129135A0 (ru)
IS (1) IS5009A (ru)
NO (1) NO312961B1 (ru)
NZ (1) NZ334798A (ru)
PL (1) PL332553A1 (ru)
SK (1) SK42899A3 (ru)
TR (1) TR199900724T2 (ru)
UA (1) UA52698C2 (ru)
WO (1) WO1998015542A1 (ru)
ZA (1) ZA978877B (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA73749C2 (en) * 1999-11-01 2005-09-15 Diarylenines
US6495582B1 (en) * 2000-09-15 2002-12-17 Vertex Pharmaceuticals Incorporated Isoxazole compositions useful as inhibitors of ERK
US20040106794A1 (en) * 2001-04-16 2004-06-03 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
UA78529C2 (en) * 2001-10-10 2007-04-10 Wyeth Corp Derivatives of [[2-(amino-3,4-dioxo-1-cyclobutene-1-yl)amino]alkyl] acid for treating pain
US20040152694A1 (en) * 2003-02-04 2004-08-05 Istvan Kurucz Methods and compositions for treating inflammatory disorders of the airways
CN1863810B (zh) 2003-04-09 2010-12-01 惠氏公司 [2-(8，9-二氧代-2，6-二氮杂二环[5.2.0]壬-1(7)-烯-2-基)烷基]膦酸衍生物及其作为n-甲基-d-天冬氨酸(nmda)受体拮抗剂的应用
TW200514775A (en) 2003-10-22 2005-05-01 Wyeth Corp Methods for the preparation of {2-[(8,9)-dioxo-2,6-diaza-bicyclo[5.2.0]-non-1(7)-en-2-yl]ethyl} phosphonic acid and esters thereof
CN101277952B (zh) * 2005-10-11 2011-09-28 弗·哈夫曼-拉罗切有限公司 异*唑衍生物
WO2009092324A1 (en) * 2008-01-16 2009-07-30 Hong Kong University Of Science And Technology Oxazolidine derivatives as nmda antagonists
EP2338492A1 (en) 2009-12-24 2011-06-29 Universidad del Pais Vasco Methods and compositions for the treatment of alzheimer
TW201609719A (zh) * 2014-05-28 2016-03-16 美國禮來大藥廠 作為ＴＡＲＰ－γ８依賴性ＡＭＰＡ受體拮抗劑之６－經取代－３Ｈ－１，３－苯并噻唑－２－酮化合物
US10442768B2 (en) 2016-01-21 2019-10-15 Agro-Kanesho Co., Ltd. Method for producing 2-aminonicotinic acid benzyl ester derivative

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0456519T3 (da) 1990-05-11 1994-11-07 Sankyo Co Piperidyloxy- og quinuclidinyloxyisoxazolderivater, deres fremstilling og deres terapeutiske anvendelse
DE69325662T2 (de) 1992-10-23 2000-02-10 Merck Sharp & Dohme Ltd., Hoddesdon Dopamin rezeptor subtyp liganden
DK124393D0 (da) * 1993-11-03 1993-11-03 Lundbeck & Co As H Compounds

Also Published As

Publication number Publication date
JP2001501630A (ja) 2001-02-06
DE69718338D1 (de) 2003-02-13
UA52698C2 (ru) 2003-01-15
AU733004B2 (en) 2001-05-03
BR9712198A (pt) 1999-08-31
CN1238766A (zh) 1999-12-15
IS5009A (is) 1999-03-23
ZA978877B (en) 1998-04-17
ES2189978T3 (es) 2003-07-16
EP0934286A1 (en) 1999-08-11
NO991561D0 (no) 1999-03-30
EA001625B1 (ru) 2001-06-25
BG103348A (en) 1999-11-30
WO1998015542A1 (en) 1998-04-16
EP0934286B1 (en) 2003-01-08
NZ334798A (en) 2000-06-23
HUP0000084A3 (en) 2001-12-28
CA2268028C (en) 2003-03-18
DE69718338T2 (de) 2003-10-16
NO312961B1 (no) 2002-07-22
ATE230734T1 (de) 2003-01-15
PL332553A1 (en) 1999-09-13
HUP0000084A2 (hu) 2000-06-28
NO991561L (no) 1999-06-04
KR20000048908A (ko) 2000-07-25
CZ116899A3 (cs) 1999-09-15
US6200999B1 (en) 2001-03-13
SK42899A3 (en) 1999-08-06
TR199900724T2 (xx) 1999-06-21
CA2268028A1 (en) 1998-04-16
AU4451797A (en) 1998-05-05
AR008880A1 (es) 2000-02-23
IL129135A0 (en) 2000-02-17

Similar Documents

Publication Publication Date Title
EA199900358A1 (ru) Производные 3-алкоксиизоксазол-4-илзамещенных 2-аминокарбоновых кислот
DE60113514T2 (de) 2-oxo-1-pyrrolidinderivate, verfahren zu ihrer herstellung und ihre verwendung
RU2002124522A (ru) Производные 2-оксо-1-пирролидина, способ их получения и применения
ES2147759T3 (es) Heterociclos no aromaticos sustituidos con aminometileno y uso como antagonistas de la sustancia p.
ATE371659T1 (de) Pyrazolotriazinderivate als gaba-rezeptorliganden
PT96001A (pt) Processo para a preparacao de derivados de isoquinolina condensada com um anel carbociclico
OA09523A (fr) Nouveaux dérivés de l'érythromycine leur procédé de préparation les nouveaux intermediaires obtenus et leur application comme médicaments
DK0743853T3 (da) Forbindelser, der er aktive ved et nyt sted på receptorstyrede calciumkanaler, og som er nyttige til behandling af neurologiske tilstande og sygdomme
CA2488167A1 (en) Prodrugs of excitatory amino acids
MA30703B1 (fr) Dérivés de 5,6-bisaryl-2-pyridine-carboxamide, leur préparation et leur application en thérapeutique comme antagonistes des recepteurs a l'urotensine ii.
PT976745E (pt) Derivado de 4-tetra-hidropiridilpirimidina
IL140042A0 (en) Carboxylic acids and carboxylic acid isosteres of n-heterocyclic compounds
ATE64391T1 (de) Azacyclische verbindungen, verfahren zu ihrer herstellung und ihre verwendung als pharmazeutisches mittel.
DE69927044D1 (de) Verfahren zur racemizierung
AP2003002873A0 (en) Pregabalin lactose conjugates
NZ504316A (en) Pyrimidine substituted carboxylic acid derivatives which have amido side-chains useful as endothelin receptor antagonists
ES2140620T3 (es) Derivados de oxopiridinylquinoxalina.
BR9607443A (pt) Composto de 4-aminotetraidrobenzisoxazol ou-isatiazol composição farmacêutica e utilização do composto
CA2168514A1 (en) Isocarbacyclin derivatives
WO2007146376A3 (en) Substituted 3-cyanopyridines as protein kinase inhibitors
ATE147392T1 (de) Organosilan-derivate, diese enthaltende pharmazeutische mittel und verfahren zu ihrer herstellung
BRPI0406670A (pt) Processo para a preparação de lactamas policìclicas fundidos com arila
FI915646A0 (fi) Menetelmä terapeuttisesti käyttökelpoisten 4,5,6,11-tetrahydrobentso[6,7]syklo-okta[1,2-b]tiofeeni-6,11-imiinien ja 6,11-dihydrobentso[6,7]syklo-okta[1,2-b]tiofeeni-6,11-imiinien valmistamiseksi ja siinä käyttökelpoinen välituoteyhdiste
DE69210214D1 (de) 2-(2,3-dicarboxycyclopropyl)-glycin und ein verfahren zu ihrer herstellung
EA200600373A1 (ru) Производные 8-хлор-2,3-бензодиазепина

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY RU